Ozols RF - Search Results

1

Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.

Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX. Cai KQ, et al. Among authors: ozols rf. Gynecol Oncol. 2006 Nov;103(2):719-28. doi: 10.1016/j.ygyno.2006.03.053. Epub 2006 May 12. Gynecol Oncol. 2006. PMID: 16698071

2

Ovarian cancer biology.

Perez RP, Godwin AK, Hamilton TC, Ozols RF. Perez RP, et al. Among authors: ozols rf. Semin Oncol. 1991 Jun;18(3):186-204. Semin Oncol. 1991. PMID: 2042060 Review. No abstract available.

3

Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.

Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ, Hamilton TC. Yao KS, et al. Among authors: ozols rf. Cancer Res. 1995 Oct 1;55(19):4367-74. Cancer Res. 1995. PMID: 7671249

4

Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.

Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK. Schultz DC, et al. Among authors: ozols rf. Cancer Res. 1995 May 15;55(10):2150-7. Cancer Res. 1995. PMID: 7743516

5

Research directions in epithelial ovarian cancer.

Ozols RF. Ozols RF. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S168-73. doi: 10.1006/gyno.1994.1358. Gynecol Oncol. 1994. PMID: 7835803 Review.

6

Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.

Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC. Johnson SW, et al. Among authors: ozols rf. Cancer Res. 1994 Nov 15;54(22):5911-6. Cancer Res. 1994. PMID: 7954422

7

Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.

Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ. Yao K, et al. Among authors: ozols rf. Cancer Res. 1993 Aug 15;53(16):3662-6. Cancer Res. 1993. PMID: 8101766 Clinical Trial.

8

Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.

Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Hamaguchi K, et al. Among authors: ozols rf. Cancer Res. 1993 Nov 1;53(21):5225-32. Cancer Res. 1993. PMID: 8106143

9

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.

Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC. Johnson SW, et al. Among authors: ozols rf. Biochem Pharmacol. 1994 Feb 11;47(4):689-97. doi: 10.1016/0006-2952(94)90132-5. Biochem Pharmacol. 1994. PMID: 8129746

10

Clinical reversal of drug resistance in ovarian cancer.

Ozols RF, O'Dwyer PJ, Hamilton TC. Ozols RF, et al. Gynecol Oncol. 1993 Oct;51(1):90-6. doi: 10.1006/gyno.1993.1252. Gynecol Oncol. 1993. PMID: 8244181 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

274 results

Search Page

Filters